Investment Analysts’ Recent Ratings Changes for AbbVie (ABBV)

Several brokerages have updated their recommendations and price targets on shares of AbbVie (NYSE: ABBV) in the last few weeks:

• 2/5/2026 – AbbVie had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein.
• 2/5/2026 – AbbVie had its price target lowered by analysts at UBS Group AG from $240.00 to $230.00. They now have a “neutral” rating on the stock.
• 2/5/2026 – AbbVie had its price target raised by analysts at Morgan Stanley from $269.00 to $270.00. They now have an “overweight” rating on the stock.
• 2/4/2026 – AbbVie had its price target lowered by analysts at Evercore Inc from $232.00 to $228.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – AbbVie had its “neutral” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $223.00 price target on the stock.
• 1/27/2026 – AbbVie had its price target lowered by analysts at Citigroup Inc. from $235.00 to $230.00. They now have a “neutral” rating on the stock.
• 1/21/2026 – AbbVie had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – AbbVie was given a new $275.00 price target on by analysts at Berenberg Bank.
• 1/15/2026 – AbbVie had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $258.00 price target on the stock.
• 1/13/2026 – AbbVie had its “neutral” rating reaffirmed by analysts at UBS Group AG.
• 1/7/2026 – AbbVie is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $240.00 price target on the stock.
• 1/3/2026 – AbbVie was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/13/2025 – AbbVie was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/12/2025 – AbbVie had its price target raised by analysts at Morgan Stanley from $261.00 to $269.00. They now have an “overweight” rating on the stock.

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.